Page last updated: 2024-08-24

valsartan and Diabetic Nephropathies

valsartan has been researched along with Diabetic Nephropathies in 81 studies

Research

Studies (81)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (2.47)18.2507
2000's32 (39.51)29.6817
2010's33 (40.74)24.3611
2020's14 (17.28)2.80

Authors

AuthorsStudies
Cai, J; Jiang, D; Sun, F1
Jiang, Y; Liu, C; Yu, M1
Kozak, PM; Stacey, RB; Upadhya, B; Vasan, RS1
Chen, J; Chen, S; Li, G; Qin, S; Qin, Y; Wang, S1
Ai, SS; Cui, T; Gao, RR; Han, C; Hu, HZ; Li, W; Liu, Y; Shen, Z; Sui, GY1
Su, F; Xia, Q1
Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H1
Ding, Y; Duan, FY; Huang, SL; Jia, PP; Ren, XQ; Song, CD; Song, D; Wang, YX; Zhai, WS1
Hu, L; Liu, G; Wei, Y1
Chen, Y; Han, X; Liu, J; Ma, Y; Xie, D; Xu, H1
Jiang, Z; Li, X; Meng, F; Tan, Z1
Bo, W; Chen, H; Hongbao, L; Li, L; Peng, Z; XiaoWei, L; Xiong, C1
Ding, Z; Li, Y; Liu, R; Wang, Q; Zang, Y; Zhang, G; Zhang, X1
Chen, H; Liu, F; Ma, Q; Yang, H1
Keshawy, MM; Makary, S; Tawfik, MK1
Liu, ZY; Shan, C; Wu, H; Yu, J; Zhang, KQ; Zhu, Q1
An, S; Duan, L; Gao, Y; Liu, J; Liu, Y; Tian, L; Wang, J; Wang, S; Wei, S; Zhou, S1
Ahmad, SNS; Argani, H; Aslani, S; Ghorbani Haghjo, A; Jigheh, ZA; Mesgari Abbasi, M; Panah, F; Rashedi, J; Roshangar, L; Sanajou, D1
Aparicio, MC; Aucella, F; Battaglia, G; Belviso, A; Bossi, AC; Carrara, F; Cortinovis, M; David, S; Diadei, O; Gaspari, F; Gregoric, N; Iliev, IP; Janez, A; Manunta, P; Martinetti, D; P Barlovic, D; Parvanova, A; Peraro, F; Perna, A; Pisani, A; Remuzzi, G; Riccio, E; Rota, S; Ruggenenti, P; Ruggiero, B; Satta, A; Stucchi, N; Trevisan, R; Trillini, M1
Aroor, AR; Chandrasekar, B; Das, NA; DeMarco, VG; Habibi, J; Hayden, MR; Johnson, MS; Manrique-Acevedo, CM; Nistala, R; Wiedmeyer, C1
Abdo, M; Hassan, WA; Makary, S; Tawfik, MK1
Ge, Y; Hou, J; Jin, B; Li, S; Liu, Z; Shi, M; Xie, H; Zhang, H1
El-Maraghy, SA; Motawi, TK; Senousy, MA1
Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G1
Cheung, AK; Huang, Y; Liu, X; Zhou, G1
Howard, A; Kopp, JB; Levi, M; Li, C; Qiu, L; Solis, N; Wang, W; Wang, X1
Guo, T; Hao, P; Kong, J; Li, D; Meng, X; Yang, J; Zhang, C; Zhang, K; Zhang, M; Zhang, Y1
Guo, ZA; Li, Y; Liu, G; Meng, FC; Peng, SL; Yu, CJ1
Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY1
Hou, XL; Jin, H; Wu, J; Zhang, B; Zhang, HB; Zhang, HN1
Batenburg, WW; Bhaggoe, UM; Clahsen-van Groningen, MC; Danser, AH; de Vries, R; Friesema, EC; Garrelds, IM; Hoorn, EJ; Leijten, FP; Roksnoer, LC; van Gool, JM; van Veghel, R1
Peng, W; Qiao, H; Wang, L; Wang, Y; Wu, C; Xu, Z; Zhang, X1
Galle, J1
Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, JL; Zhang, Y1
Abadir, PM; Abdel-Rahman, EM; Siragy, HM1
Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y1
Chihara, K; Dan, T; Izuhara, Y; Kurokawa, K; Miyata, T; Ohtomo, S; Robert, A; Tominaga, N; Van Ypersele de Strihou, C1
Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E1
Kamal, F; Morioka, T; Oite, T; Piao, H; Yanakieva-Georgieva, N1
Blanco-Colio, LM; Carrero, JJ; Celik, T; Egido, J; Eyileten, T; Martín-Ventura, JL; Moreno, JA; Saglam, M; Sonmez, A; Yaman, H; Yenicesu, M; Yilmaz, MI1
Gao, Q; Liu, Z; Qin, W; Shen, W; Wang, J; Wang, S; Zeng, C; Zhang, M; Zheng, C; Zhu, X1
Biro, S; Ikeda, Y; Kono, S; Otonari, T; Saikawa, T; Sasaki, J1
Aizawa, Y; Suzuki, K1
Huang, J; Matavelli, LC; Siragy, HM1
Higashi, K; Hiroo, K; Kushiyama, T; Oda, T; Yamamoto, K1
Dejima, T; Fujikawa, T; Haku, S; Kanaoka, T; Kondoh, S; Konno, Y; Maeda, A; Mitsuhashi, H; Mizushima, S; Moriya, T; Ogawa, N; Ohsawa, M; Okano, Y; Ozawa, M; Suzuki, D; Tamura, K; Tanaka, K; Toyoda, M; Umemura, S; Umezono, T; Wakui, H; Yamakawa, T; Yanagi, M1
Cheng, YN; Gao, JJ; Jiao, B; Wang, YS; Zhang, QZ1
Chen, H; Li, H; Liu, Z; Tang, L; Yang, B; Yi, R1
Kumagai, H; Matsubara, H; Oda, T; Ohshima, N; Senda, M; Tadano, H; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K1
Imanishi, M; Kitabayashi, C; Konishi, Y; Maeda, I; Masada, M; Morikawa, T; Nishiyama, A; Okada, N; Shirahashi, N; Wilcox, CS1
Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T1
Bai, WW; Sun, HL; Xiang, GD; Yue, L; Zhao, LS1
Aizawa, Y; Ikarashi, T; Kaneko, S; Nakagawa, O; Souda, S; Suzuki, K1
Viberti, G; Wheeldon, NM1
Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H1
Andersen, S; Jacobsen, P; Jensen, BR; Parving, HH1
Abadir, P; Awad, A; Siragy, HM; Webb, R1
Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV1
Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM1
Suzuki, H1
Awad, AS; Carey, RM; Siragy, HM; Webb, RL1
Temple, R1
Hausberg, M; Hohage, H; Kosch, M1
Böger, RH; Maas, R; Quispe-Bravo, S; Schwedhelm, E; Skamira, C1
Jacobsen, PK; Parving, HH; Rossing, P1
Ito, S; Kato, T; Mori, T; Nako, K; Ogawa, S; Takeuchi, K1
Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F1
Coll, JR; Estacio, RO; Schrier, RW; Tran, ZV1
Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, HY; Zhang, Y1
Inaba, M; Inukai, K; Izumida, T; Katayama, S; Noguchi, Y; Yagi, S; Yamaguchi, M; Yamamoto, H1
Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T1
Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C1
Allen, TJ; Cao, Z; Cooper, ME; Hulthen, UL; Youssef, S1
Cooper, ME; Gibbs, NJ; Kelly, DJ; Skinner, SL; Wilkinson-Berka, JL1
Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Tolcos, M; Wilkinson-Berka, JL1
Lin, S; Wen, H1
Dagistanli, FK; Erek, E; Kalender, B; Oztürk, M; Tunçdemir, M; Uysal, O; Yegenaga, I1

Reviews

7 review(s) available for valsartan and Diabetic Nephropathies

ArticleYear
Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
    BMC endocrine disorders, 2021, Aug-31, Volume: 21, Issue:1

    Topics: Antihypertensive Agents; Antioxidants; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Kidney; Thioctic Acid; Valsartan

2021
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
    Current hypertension reports, 2022, Volume: 24, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Reduction of proteinuria with angiotensin receptor blockers.
    Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5 Suppl 1

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2008
[Recent advance in kidney and hypertension research].
    Nihon Jinzo Gakkai shi, 2012, Volume: 54, Issue:1

    Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Agonists; Catheter Ablation; Cerebrovascular Circulation; Chronic Disease; Diabetic Nephropathies; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Kidney Diseases; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2012
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
    Kardiologiia, 2003, Volume: 43, Issue:2

    Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Placebos; Prognosis; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2003
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
    Kardiologiia, 2004, Volume: 44, Issue:1

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan

2004
Angiotensin type 1 receptor blockers in chronic kidney disease.
    Contributions to nephrology, 2004, Volume: 143

    Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Kidney Diseases; Losartan; Tetrazoles; Valine; Valsartan

2004

Trials

22 trial(s) available for valsartan and Diabetic Nephropathies

ArticleYear
Curative Effects of Valsartan Alone or Combined with Alpha-lipoic Acid on Inflammatory Cytokines and Renal Function in Early-stage Diabetic Kidney Disease.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019, Volume: 29, Issue:10

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; China; Cytokines; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Kidney Function Tests; Male; Middle Aged; Thioctic Acid; Valsartan

2019
Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2020, Volume: 119, Issue:3

    Topics: Adult; Aged; Antihypertensive Agents; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Proteinuria; Renin-Angiotensin System; Treatment Outcome; Tripterygium; Valsartan

2020
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:5

    Topics: Adult; Aged; Benzazepines; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Italy; Kidney Function Tests; Male; Middle Aged; Slovenia; Treatment Outcome; Valsartan

2019
Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial.
    Journal of translational medicine, 2013, May-31, Volume: 11

    Topics: Adult; Aged; Diabetic Nephropathies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Prospective Studies; Tetrazoles; Treatment Outcome; Tripterygium; Valine; Valsartan

2013
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
    Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:11

    Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Female; Glucuronidase; Hospitals, University; Humans; Hydrochlorothiazide; Hypertension; Klotho Proteins; London; Male; Middle Aged; Phosphates; Pulse Wave Analysis; Renin-Angiotensin System; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2013
[Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2014, Volume: 34, Issue:9

    Topics: Adult; Albumins; Albuminuria; Blood Pressure; Creatinine; Diabetic Nephropathies; Drugs, Chinese Herbal; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan

2014
Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide.
    Disease markers, 2015, Volume: 2015

    Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Male; Middle Aged; Valsartan

2015
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
    Diabetes research and clinical practice, 2009, Volume: 83, Issue:1

    Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan

2009
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
    Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:7

    Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; C-Reactive Protein; Calcium Channel Blockers; Chi-Square Distribution; Cytokine TWEAK; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Serum Amyloid P-Component; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factors; Turkey; Valine; Valsartan; Vasodilation

2010
Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:9

    Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; Blood Urea Nitrogen; Collagen Type IV; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Tetrazoles; Valine; Valsartan

2010
Evaluation of dosing time-related anti-hypertensive efficacy of valsartan in patients with type 2 diabetes.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2011, Volume: 33, Issue:1

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2011
[The Shiga Microalbuminuria Reduction Trial].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68 Suppl 9

    Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Middle Aged; Prospective Studies; Rats; Tetrazoles; Valine; Valsartan

2010
Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2013, Volume: 14, Issue:1

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin Receptor Antagonists; Biopterins; Blood Pressure; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemodynamics; Humans; Kidney; Male; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Receptors, Angiotensin; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan

2013
Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.
    Diabetes research and clinical practice, 2002, Volume: 57, Issue:3

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan

2002
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
    Circulation, 2002, Aug-06, Volume: 106, Issue:6

    Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan

2002
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Journal of the American Society of Nephrology : JASN, 2003, Volume: 14, Issue:4

    Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Synergism; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan

2003
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:7

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Circadian Rhythm; Diabetic Nephropathies; Humans; Renin-Angiotensin System; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan

2006
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 47, Issue:4

    Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Single-Blind Method; Tetrazoles; Trichlormethiazide; Valine; Valsartan

2006
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    American journal of hypertension, 2006, Volume: 19, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Colorado; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2006
Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2007, Volume: 30, Issue:6

    Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Hypertension; Kidney; Middle Aged; Tetrazoles; Valine; Valsartan

2007
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
    American journal of hypertension, 2007, Volume: 20, Issue:12

    Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan

2007
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:10

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan

2008

Other Studies

52 other study(ies) available for valsartan and Diabetic Nephropathies

ArticleYear
Effects of calcium dobesilate combined with categlicine and valsartan capsules on inflammation and cellular immunity in patients with diabetic nephropathy.
    Minerva surgery, 2023, Volume: 78, Issue:1

    Topics: Calcium Dobesilate; Capsules; Diabetes Mellitus; Diabetic Nephropathies; Humans; Immunity, Cellular; Inflammation; Valsartan

2023
Effects of Valsartan on LN, FN, MDA, Renal Tissue Fibrosis, and Inflammatory Infiltration in DN Rats.
    Contrast media & molecular imaging, 2022, Volume: 2022

    Topics: Animals; Diabetic Nephropathies; Fibronectins; Fibrosis; Laminin; Male; Rats; Valsartan

2022
Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the "gut-kidney axis".
    Journal of ethnopharmacology, 2023, May-10, Volume: 307

    Topics: Animals; Blood Glucose; Chromatography, Liquid; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Glycerophospholipids; Herbal Medicine; Kidney; Rats; Saline Solution; Sphingolipids; Tandem Mass Spectrometry; Tryptophan; Valsartan

2023
Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy.
    Alternative therapies in health and medicine, 2023, Volume: 29, Issue:5

    Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Interleukin-6; Tablets; Thioctic Acid; Valsartan

2023
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, Oct-31, Volume: 38, Issue:11

    Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Kidney; Male; Mice; Natriuretic Peptides; Renal Plasma Flow; Valsartan

2023
[Effect of multi-glycosides of Tripterygium wilfordii on renal injury in diabetic kidney disease rats through NLRP3/caspase-1/GSDMD pyroptosis pathway].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2023, Volume: 48, Issue:10

    Topics: Animals; Caspase 1; Diabetes Mellitus; Diabetic Nephropathies; Glycosides; Interleukin-18; Kidney; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tripterygium; Uridine Triphosphate; Valsartan

2023
Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension.
    International immunopharmacology, 2023, Volume: 123

    Topics: Biphenyl Compounds; Delayed-Action Preparations; Diabetes Mellitus; Diabetic Nephropathies; Drug Combinations; Humans; Hypertension; Nifedipine; Tetrazoles; Valsartan

2023
Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice.
    International immunopharmacology, 2023, Volume: 115

    Topics: Angiopoietin-Like Protein 3; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Failure, Chronic; Mice; Podocytes; Reactive Oxygen Species; Streptozocin; Valsartan

2023
Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Animals; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Renal Insufficiency, Chronic; Signal Transduction; Silybin; Transforming Growth Factor beta1; Valsartan

2020
Up-regulation of matrix metalloproteinases-9 in the kidneys of diabetic rats and the association with neutrophil gelatinase-associated lipocalin.
    BMC nephrology, 2021, 06-03, Volume: 22, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Tubules, Proximal; Lipocalin-2; Male; Matrix Metalloproteinase 9; Random Allocation; Rats; Rats, Sprague-Dawley; Up-Regulation; Valsartan

2021
Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression.
    Molecular biology reports, 2021, Volume: 48, Issue:9

    Topics: Angiopoietin-Like Protein 2; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Gene Expression; Kidney; Male; NF-kappa B; Protective Agents; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 2; RNA, Messenger; Streptozocin; Toll-Like Receptor 4; Treatment Outcome; Valsartan

2021
Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation.
    International journal of molecular medicine, 2017, Volume: 40, Issue:4

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Chemokine CXCL9; Diabetic Nephropathies; Gene Expression Regulation; Glycation End Products, Advanced; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Membrane Proteins; Mice; Podocytes; Proto-Oncogene Proteins c-bcl-2; Receptors, Angiotensin; Receptors, CXCR3; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha; Tyrphostins; Valsartan

2017
Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice.
    Molecular and cellular endocrinology, 2018, 09-05, Volume: 472

    Topics: Angiotensin Receptor Antagonists; Animals; Base Sequence; Biomarkers; Diabetic Nephropathies; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Matrix Metalloproteinase 9; Mice, Inbred C57BL; MicroRNAs; Myocardium; Valsartan

2018
FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
    Journal of physiology and biochemistry, 2018, Volume: 74, Issue:3

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Glomerular Filtration Barrier; Injections, Intraperitoneal; Macrophages; Male; Microscopy, Fluorescence; Phosphorylation; Podocytes; Protein Processing, Post-Translational; Random Allocation; Rats, Wistar; Receptor for Advanced Glycation End Products; Renal Insufficiency; Transcription Factor RelA; Valsartan

2018
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
    Cardiovascular diabetology, 2019, 03-25, Volume: 18, Issue:1

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Biomarkers; Biphenyl Compounds; Blood Glucose; Diabetic Nephropathies; Disease Models, Animal; Drug Combinations; Fibrosis; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Neprilysin; Nitrosative Stress; Oxidative Stress; Protease Inhibitors; Proteinuria; Rats, Zucker; Tetrazoles; Time Factors; Valsartan

2019
Angiotensin blockade attenuates diabetic nephropathy in hypogonadal adult male rats.
    Canadian journal of physiology and pharmacology, 2019, Volume: 97, Issue:8

    Topics: Angiotensin II; Angiotensins; Animals; Collagen Type IV; Diabetic Nephropathies; Estradiol; Follicle Stimulating Hormone; Glycated Hemoglobin; Hypogonadism; Kidney; Letrozole; Luteinizing Hormone; Male; NF-kappa B; Organ Size; Oxidative Stress; Rats; Signal Transduction; Testosterone; Transforming Growth Factor beta1; Valsartan

2019
Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
    Journal of biochemical and molecular toxicology, 2013, Volume: 27, Issue:7

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Gene Expression Regulation, Enzymologic; Kidney; Male; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan

2013
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
    Clinical science (London, England : 1979), 2014, Volume: 126, Issue:10

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Extracellular Matrix Proteins; Fibronectins; Gene Expression Regulation; Inflammation; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Cortex; Kidney Glomerulus; Membrane Proteins; Mice; Oxidative Stress; Plasminogen Activator Inhibitor 1; Podocytes; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan; WT1 Proteins

2014
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2014, Volume: 15, Issue:4

    Topics: Albumins; Amides; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fumarates; Inflammation; Lipid Metabolism; Male; Membrane Proteins; Mesangial Cells; Mice, Inbred DBA; Podocytes; Protective Agents; Proteinuria; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2014
Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade.
    Kidney international, 2015, Volume: 87, Issue:2

    Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Proliferation; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Male; Mesangial Cells; Oxidative Stress; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1; Valsartan; Vascular Endothelial Growth Factor A

2015
Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:1

    Topics: Adult; Aged; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal Agents; Tacrolimus; Valsartan

2016
Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.
    Clinical science (London, England : 1979), 2016, 07-01, Volume: 130, Issue:14

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Combinations; Neprilysin; Rats; Rats, Sprague-Dawley; Streptozocin; Tetrazoles; Valsartan

2016
The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2016, Volume: 17, Issue:3

    Topics: Diabetic Nephropathies; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Protective Agents; Valsartan

2016
[Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
    Zhonghua yi xue za zhi, 2008, Feb-26, Volume: 88, Issue:8

    Topics: Animals; Antihypertensive Agents; Apoptosis; Apoptosis Regulatory Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Immunosuppressive Agents; Kidney; Male; Mycophenolic Acid; NF-kappa B; Random Allocation; Rats; Rats, Wistar; Tetrazoles; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Valine; Valsartan

2008
Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2008, Volume: 295, Issue:5

    Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin; Kidney; Male; Microdialysis; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan

2008
Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
    Nephrology (Carlton, Vic.), 2009, Volume: 14, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypertension; Linear Models; Male; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan

2009
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
    Journal of hypertension, 2010, Volume: 28, Issue:7

    Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Fumarates; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan

2010
Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
    Nephron. Experimental nephrology, 2010, Volume: 115, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calpain; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Inflammation; Kidney Glomerulus; Male; NF-kappa B; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Streptozocin; Tetrazoles; Transcription Factor RelA; Valine; Valsartan

2010
Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:11

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight; Chemokine CCL2; Desmin; Diabetic Nephropathies; Diterpenes; Epoxy Compounds; Glomerular Filtration Rate; Immunohistochemistry; Kidney; Lipids; Liver; Mice; Mice, Inbred C57BL; Microscopy, Electron; Phenanthrenes; Podocytes; Reactive Oxygen Species; T-Lymphocytes; Tetrazoles; Valine; Valsartan

2010
Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade.
    Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:4

    Topics: Animals; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Hyperglycemia; Male; Mesangial Cells; Oligopeptides; Prorenin Receptor; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1; Up-Regulation; Valine; Valsartan

2011
Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2011, Volume: 33, Issue:4

    Topics: Albuminuria; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Indoles; Kidney; Lipids; Male; Middle Aged; Pilot Projects; Prospective Studies; Regression Analysis; Tetrazoles; Valine; Valsartan

2011
Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-β1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels.
    Bioscience trends, 2011, Volume: 5, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Culture Techniques; Cells, Cultured; Chemokine CCL2; Culture Media; Diabetic Nephropathies; Epithelial Cells; Glucose; Glutathione; Malondialdehyde; Mesangial Cells; Oxidative Stress; Rats; Reactive Oxygen Species; Superoxide Dismutase; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan

2011
Valsartan inhibited HIF-1α pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:1

    Topics: Animals; Blood Glucose; Blotting, Western; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin-1; Gene Expression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kidney; Male; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Streptozocin; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan

2012
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
    Clinical and experimental nephrology, 2013, Volume: 17, Issue:1

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dihydropyridines; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Glucagon; Glucose Transporter Type 1; Glycated Hemoglobin; Glycogen; Hypertension; Kidney; Male; Norepinephrine; Proteinuria; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan

2013
Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin II type 1 receptor antibody.
    Chinese medical journal, 2012, Volume: 125, Issue:19

    Topics: Aged; Autoantibodies; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Metoprolol; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta-1; Tetrazoles; Valine; Valsartan

2012
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
    Journal of hypertension, 2003, Volume: 21, Issue:1

    Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Kidney Glomerulus; Male; Membrane Proteins; Proteins; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sclerosis; Systole; Tetrazoles; Valine; Valsartan; Verapamil

2003
The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats.
    Endocrinology, 2003, Volume: 144, Issue:6

    Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Space; Hypertension, Renal; Kidney; Male; Microdialysis; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan

2003
Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
    Journal of hypertension, 2004, Volume: 22, Issue:8

    Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Fluid; Kidney; Losartan; Nitric Oxide; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan

2004
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
    MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28

    Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Renal Dialysis; Tetrazoles; Valine; Valsartan

2004
How FDA currently makes decisions on clinical studies.
    Clinical trials (London, England), 2005, Volume: 2, Issue:4

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Child; Clinical Trials as Topic; Diabetic Nephropathies; Evidence-Based Medicine; Heart Failure; Humans; Propanolamines; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan

2005
[Hypertension and diabetic nephropathy, a dangerous duo].
    Medizinische Klinik (Munich, Germany : 1983), 2005, Nov-15, Volume: 100, Issue:11

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; Male; Metabolic Syndrome; Ramipril; Tetrazoles; Valine; Valsartan

2005
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
    Vascular medicine (London, England), 2005, Volume: 10 Suppl 1

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Benzimidazoles; Benzoates; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Endothelium, Vascular; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Renal Insufficiency; Telmisartan; Tetrazoles; Valine; Valsartan

2005
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
    Kidney international, 2006, Volume: 70, Issue:3

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Enalapril; Female; Glycation End Products, Advanced; Mice; Mice, Inbred C57BL; Mice, Obese; Pyridoxamine; Tetrazoles; Valine; Valsartan; Vitamin B Complex

2006
[Valsartan: arguments for the high dose concept].
    MMW Fortschritte der Medizin, 2006, Dec-14, Volume: 148, Issue:51-52

    Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Humans; Hypertension, Renal; Proteinuria; Tetrazoles; Valine; Valsartan

2006
Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
    Chinese medical journal, 2007, Jun-05, Volume: 120, Issue:11

    Topics: Animals; Chemokine CCL2; Desmin; Diabetic Nephropathies; Drug Therapy, Combination; Immunohistochemistry; Male; Membrane Proteins; Mycophenolic Acid; Podocytes; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan

2007
[New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschritte der Medizin, 2007, Nov-15, Volume: 149, Issue:46

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Prognosis; Tetrazoles; Treatment Outcome; Valine; Valsartan

2007
[Risk oriented therapy of hypertension. Lowering blood pressure and risk].
    MMW Fortschritte der Medizin, 2007, Nov-15, Volume: 149, Issue:46

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetic Nephropathies; Humans; Hypertension; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan

2007
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
    Diabetes, 1997, Volume: 46, Issue:10

    Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan

1997
Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:7

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Female; Heterozygote; Kidney; Perindopril; Rats; Renin; Tetrazoles; Valine; Valsartan

2001
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
    Kidney international, 2002, Volume: 61, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Apoptosis; Atrophy; Autoradiography; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epidermal Growth Factor; Female; Fibrosis; Gene Expression; In Situ Hybridization; In Situ Nick-End Labeling; Kidney Tubules; Nephritis, Interstitial; Perindopril; Rats; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan

2002
[Renal protective effect of valsartan in diabetic rats].
    Zhonghua nei ke za zhi, 1999, Volume: 38, Issue:3

    Topics: Animals; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Fibronectins; Kidney; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan

1999
Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
    Acta histochemica, 2002, Volume: 104, Issue:2

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; Immunoenzyme Techniques; Immunohistochemistry; Kidney; Organ Size; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan

2002